Wealth Awesome
TSX closed
Loading markets…
Interactive Brokers: IBKR clients beat the S&P 500 in 2025 — 19.20% average client return vs 17.9% for the index, net of commissions and charges.
Stocks

Eupraxia Pharmaceuticals Inc EPRX Earnings Beat Estimates by 8.3%

By Wealth Awesome -

Follow live quotes and coverage.

Stocks & ETFs:EPRX.TO

Follow EPRX

Photos provided by Pexels

Eupraxia’s September-quarter loss came in slightly below expectations. But the result does little to answer the bigger question for this clinical-stage biotech: what will its December trial update show?

Eupraxia Pharmaceuticals Inc. (TSX: EPRX) reported a fiscal third-quarter 2026 loss of C$0.33 per share for the period ended September 30, compared with an estimated loss of C$0.36. That’s an 8.3% positive surprise. The company remains unprofitable, with trailing 12-month EPS of -C$1.49. For investors, clinical progress and financing are likely to matter more than one quarter’s loss per share. Eupraxia expects an interim analysis from its EP-104GI Phase 2b RESOLVE trial in December and says its cash runway extends into the second half of 2028.

Recent earnings trend

Eupraxia Pharmaceuticals Inc

EPRX.TO

Full stock page →

EPRX.TO

Eupraxia Pharmaceuticals Inc

Source:WealthAwesomeWealthAwesome
↓ $0.79 (-8.25%)
120 day period
$8.22$10.61$12.99Jun 1Aug 26Nov 19

Market cap

$710.35M

52W high

$13.08

52W low

$7.85

1W change

-20.97%

Beta

1.33

Analyst Price Targets

Based on analyst covering EPRX · as of Nov 18, 2026

📈

Wall Street analysts forecast EPRX stock price to rise 184.9% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$17.43

+184.9% Upside

Previously C$16.33 on Sep 28, 2026

Current Price

C$6.12

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on EPRX's historical volatility

HistoricalForecast68%95%
C$2.56C$6.26C$9.96C$13.66C$17.37C$21.07TodayJul 14Sep 17Nov 19Jan 1Feb 14Mar 29

30-Day Vol

85.7%

Annualized

90-Day Vol

81.0%

Annualized

Trend (90d)

-50.0%

Annualized drift

90d Mean

C$7.34

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$8.27C$6.15 – C$11.12
60 trading daysC$7.79C$5.13 – C$11.84
90 trading daysC$7.34C$4.40 – C$12.26

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Analyst coverage: 8 analyst(s) cover this name; upcoming EPS consensus is available.

Beat estimates in 1 of the last 4 comparable quarter(s).

Fiscal periodReport dateActual EPSEstimateSurprise
2026-12-312027-03-16—-0.2800—
2026-09-302026-11-10-0.3300-0.3600+8.3%
2026-06-302026-08-11-0.3200-0.3200+0.0%
2026-03-312026-05-07-0.3201-0.1900-68.5%
2025-12-312026-03-12-0.5000-0.2200-127.3%
2025-09-302025-11-04-0.2700-0.2700+0.0%
-0.5000-0.25000.0000 24-1225-0325-0625-0925-1226-0326-0626-09 Estimate Actual (≥0) Actual (<0) Wealth Awesome

Investor takeaway: EPRX’s earnings beat was modest. It doesn’t mean the company is profitable or change its clinical-stage profile. Eupraxia has beaten estimates in one of its last four reported quarters; the other three were in line with or below estimates. The December interim analysis is the next major clinical catalyst. The company has also established an at-the-market equity program, giving it another financing option. Investors should consider the trial update and potential share dilution alongside the earnings result.

C$0.33 loss per share

Eupraxia reported a loss of C$0.33 per share, C$0.03 narrower than the C$0.36 estimate. That’s an 8.3% positive surprise. Trailing 12-month EPS remains -C$1.49.

Bull case

Eupraxia has enrolled all 120 patients in the blinded Phase 2b portion of its EP-104GI trial. The company expects an interim analysis in December and reiterated that its cash runway extends into the second half of 2028. That gives it time to advance the program without an immediate stated need for financing. The quarterly loss also came in below the estimate.

Bear case

Eupraxia is still reporting losses, and the small EPS beat matters less than the trial results that will shape the outlook for this clinical-stage company. It has missed estimates in three of its last four reported quarters, including a larger-than-expected loss in March 2026. The ATM equity program gives the company another way to raise funds, but issuing shares could dilute existing investors. EPRX.TO also closed at C$6.12, below its 50-day and 200-day moving averages.

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: November 20, 2026
Last Updated: November 20, 2026

Core portfolio

Awesome Portfolio™

14.8% a year since 2017, against 9.7% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+14.8%

Awesome Portfolio™

+9.7%

S&P/TSX

+5.0 pp better a year

Total return

+254%

Awesome Portfolio™

+134%

S&P/TSX

+119 pp better than the TSX

2017-07-31 to 2026-09-29, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-29
-11.7%42.5%96.7%150.9%205.1%259.3%Jul 17Oct 19Feb 22Jun 24Sep 26